Updates are available Correction dated 2023-11-16
Click to view Correction: https://doi.org/10.1038/s41598-023-47251-0
-
Authors
Ambrus-Aikelin, Geza
Takeda, Katsuyuki
Joetham, Anthony
Lazic, Milos
Povero, Davide
Santini, Angelina M.
Pranadinata, Rama
Johnson, Casey D.
McGeough, Matthew D.
Beasley, Federico C.
Stansfield, Ryan
McBride, Christopher
Trzoss, Lynnie
Hoffman, Hal M.
Feldstein, Ariel E.
Stafford, Jeffrey A.
Veal, James M.
Bain, Gretchen
Gelfand, Erwin W.
- License Information
-
More Information
Article History
Received: 3 March 2023
Accepted: 31 July 2023
First Online: 19 August 2023
Change Date: 16 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-023-47251-0
Competing interests
: G.A.-A., M.L., D.P., A.S., R.P., F.C.B., R.S., C.M., L.T., J.A.S., J.M.V., and G.B. were employees of Jecure Therapeutics when this work was performed. G.A.-A., M.L., D.P., A.S., R.P., R.S., C.M., L.T., A.E.F., J.A.S., J.M.V., and G.B. were shareholders of Jecure Therapeutics when this work was performed. A.E.F is an employee and stockholder of Novo Nordisk.
